Anti-pvrig antibody and use thereof

By developing anti-PVRIG antibodies with stronger affinity and activation ability, the problem that existing antibodies cannot effectively activate NK cells is solved, significantly enhancing the killing function of NK cells and achieving stronger therapeutic effects.

WO2024245388A1PCT designated stage expired Publication Date: 2024-12-05INNOVENT BIOLOGICS (SUZHOU) CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/096603
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The existing IgG4 anti-PVRIG antibodies cannot fully activate NK cells, resulting in insufficient killing effect of NK and insufficient clinical efficacy. It is urgent to require higher antibodies to activate NK cells to enhance the therapeutic effect.

Method used

Develop antibodies and antigen-binding fragments with stronger affinity to bind to PVRIG and stronger ability to activate NK cells, and enhance the killing function of NK cells by specifically binding and blocking the binding of PVRIG to CD112.

Benefits of technology

The new antibodies significantly enhance the activation and killing functions of NK cells, can more effectively block the binding of PVRIG and CD112, improve the killing ability of tumor cells, and demonstrate stronger therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024096603-FTAPPB-I100001
    Figure PCTCN2024096603-FTAPPB-I100001
  • Figure PCTCN2024096603-FTAPPB-I100002
    Figure PCTCN2024096603-FTAPPB-I100002
  • Figure PCTCN2024096603-FTAPPB-I100003
    Figure PCTCN2024096603-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to an antibody that specifically recognizes PVRIG or an antigen-binding fragment thereof, and a preparation method therefor and the use thereof. In addition, the present invention also relates to the therapeutic and diagnostic use of the anti-PVRIG antibody or the antigen-binding fragment thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-PVRIG antibodies and their applications Technical Field

[0001] The present invention relates to antibodies that specifically recognize PVRIG, and methods for preparing and using the same. Furthermore, the present invention also relates to uses of these antibodies or antigen-binding fragments thereof. Background Art

[0002] In recent years, the function of the CD226 axis has been identified in natural killer (NK) cells and T cells. TIGIT and CD96 effectively compete with the activating receptor CD226 for binding to the necl protein CD155. PVRIG, expressed on the surface of NK cells and T cells, effectively competes with CD226 for binding to another ligand, CD112. Studies have found that PVRIG is an inhibitory receptor that exhibits greater affinity for CD112 than CD226, thereby inhibiting the tumor-killing activity of immune cells.

[0003] The poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), also known as the CD112 receptor (CD112R), belongs to the poliovirus receptor-like protein (PVR) family. PVRIG has a molecular weight of approximately 34 kDa and is composed of a single extracellular IgV domain, a transmembrane domain, and a long intracellular portion containing an ITIM domain. PVRIG is expressed on the surface of lymphocytes (such as T cells and NK cells), functions as a cell surface receptor for CD112, and is upregulated on T cells after TCR stimulation. It is a novel inhibitory immune checkpoint in humans. When PVRIG binds to CD112, an inhibitory signal is generated to weaken the immune response of NK and T cells against target cells. The ligand of PVRIG is found to be highly expressed in various cancers, such as ovarian cancer, renal cancer, lung cancer, endometrial cancer, and breast cancer.

[0004] Using anti-PVRIG antibodies to block the binding of PVRIG to CD112 is a therapeutic approach that can enhance the killing capacity of NK and T cells. COM701 is an IgG4 humanized anti-PVRIG antibody developed by Compugen, Israel, and is the first PVRIG-specific antibody approved for clinical trials. However, the IgG4 form of PVRIG antibodies cannot fully activate NK cells, resulting in a weak NK cell killing effect and ultimately a lack of significant clinical efficacy.

[0005] Therefore, there is still an urgent need to provide new anti-PVRIG antibodies with higher NK cell activation and stronger therapeutic effects, and the present invention meets these needs.

[0006] Summary of the Invention

[0007] In a first aspect, the present invention provides antibodies and antigen-binding fragments thereof targeting PVRIG, which have the following advantages:

[0008] (1) It has a stronger affinity for binding to PVRIG, thus having a stronger blocking effect on its receptor CD112;

[0009] (2) Has stronger activity in activating NK cells;

[0010] (3) It can enhance the killing function of NK cells.

[0011] In one embodiment, the present invention provides an antibody that specifically binds to PVRIG, and / or blocks the binding of PVRIG to CD112, and / or enhances T cell and NK cell activation, and / or enhances the tumor-killing activity of T cells and NK cells. In some embodiments, the anti-PVRIG antibody is a murine antibody, a chimeric antibody, a humanized antibody, or a fragment thereof.

[0012] In a second aspect, the present invention provides a pharmaceutical composition comprising (1) the antibody or antigen-binding fragment thereof according to the first aspect, and (2) a pharmaceutically acceptable carrier.

[0013] In a third aspect, the present invention provides an isolated polynucleotide molecule encoding any one of the antibodies or antigen-binding fragments thereof described in the first aspect.

[0014] In a fourth aspect, the present invention provides a vector comprising the nucleic acid molecule of the third aspect. In one embodiment, the vector is an expression vector.

[0015] In a fifth aspect, the present invention provides a host cell comprising the vector of the fourth aspect or the nucleic acid molecule of the third invention. In some embodiments, the host cell is prokaryotic, such as Escherichia coli. In other embodiments, the host cell is eukaryotic, such as HEK293 cells, CHO cells, yeast cells, or plant cells.

[0016] In a sixth aspect, the present invention provides a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of the present invention, or a therapeutically effective amount of the pharmaceutical composition of the present invention.

[0017] In a seventh aspect, the present invention provides use of an anti-PVRIG antibody or an antigen-binding fragment thereof in the preparation of a medicament for treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 shows the ability of chimeric anti-PVRIG antibodies to bind to GS-CHO-human PVRIG cells.

[0019] FIG2 shows the ability of chimeric anti-PVRIG antibodies to block the binding of PVRIG to CD112.

[0020] Figure 3 shows that chimeric anti-PVRIG increases the killing capacity of NK cells.

[0021] Figure 4 shows the ability of humanized anti-PVRIG antibodies to bind to GS-CHO-human PVRIG cells.

[0022] FIG5 shows the ability of humanized anti-PVRIG antibodies to block the binding of PVRIG to CD112.

[0023] Figure 6 shows that humanized anti-PVRIG increases the killing capacity of NK cells.

[0024] FIG7 shows the ability of humanized anti-PVRIG antibodies to mediate NK cell activation.

[0025] Figure 8 shows the ability of humanized anti-PVRIG to mediate NK cell degranulation.

[0026] Figure 9 shows the therapeutic effect of humanized anti-PVRIG antibody in the PBMC xenograft DAN-G / Claudin18.2 model, Figure 9A shows the activity of the antibody in inhibiting tumor volume, and Figure 9B shows the effect of the antibody on mouse body weight.

[0027] FIG10 shows the dose-dependent ability of anti-PVRIG antibodies to mediate NK cell killing.

[0028] Detailed Description of the Invention

[0029] Before describing the present invention in detail, it should be understood that the present invention is not limited to the specific methods and experimental conditions in this specification, because the methods and conditions can be varied. In addition, the terminology used herein is only for describing specific embodiments and is not intended to be limiting.

[0030] I. Definition

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For the purposes of the present invention, the following terms are defined below.

[0032] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 10% less than the specified numerical value and an upper limit that is 10% greater than the specified numerical value.

[0033] The term "and / or" when used to link two or more alternatives should be understood to mean any one of the alternatives or any two or more of the alternatives.

[0034] As used herein, the terms "comprising" or "including" are intended to include the recited elements, integers, or steps, but do not exclude any other elements, integers, or steps. In this document, when the terms "comprising" or "including" are used, unless otherwise indicated, the context of consisting of the recited elements, integers, or steps is also encompassed. For example, when reference is made to an antibody variable region "comprising" a specific sequence, it is intended to encompass an antibody variable region consisting of that specific sequence.

[0035] The term "PVRIG" can be used interchangeably with "CD112R", "CD112 receptor", "C7orf15", "poliovirus receptor-associated immunoglobulin domain-containing protein", etc., and refers to a protein with a single transmembrane domain and a molecular weight of approximately 34 kDa, which is composed of a single extracellular IgV domain, a transmembrane domain and a long intracellular part containing an ITIM domain, and is a member of the poliovirus receptor-like protein (PVR) family. The term "PVRIG" covers any natural PVRIG from any vertebrate source (such as human PVRIG, mouse PVRIG, crab-eating monkey PVRIG, etc.); it also covers full-length PVRIG, unprocessed PVRIG, and any form of PVRIG variants produced by processing in cells, such as splice variants or allelic variants. The extracellular segment of the human PVRIG protein refers to a fragment containing the IgV domain, and typically the extracellular segment of the human PVRIG protein contains the complete extracellular fragment of the PVRIG protein.

[0036] The term "antibody" is used in the broadest sense herein and encompasses a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity. A complete antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but may comprise fewer chains in certain circumstances, e.g., antibodies naturally occurring in camels may comprise only heavy chains.

[0037] The term "anti-PVRIG antibody" refers to an antibody that specifically binds to PVRIG. In some embodiments of the present invention, the anti-PVRIG antibody is a murine anti-PVRIG antibody. In preferred embodiments, the anti-PVRIG antibody of the present invention is a chimeric antibody or a humanized antibody comprising a human constant region, a human antibody constant region. In some embodiments, the anti-PVRIG antibody of the present invention binds to human PVRIG with high affinity and can effectively block the binding of human PVRIG to its ligand (e.g., CD112).

[0038] The term "chimeric antibody" refers to an antibody molecule in which the constant region or a portion thereof is altered, replaced or exchanged such that the antigen binding site is linked to a constant region of a different or altered class and / or species or a completely different molecule (e.g., enzyme, toxin, hormone, growth factor, drug) that imparts new properties to the chimeric antibody. For example, a mouse antibody can be made into a chimeric antibody by replacing its constant region with a constant region from a human immunoglobulin. Due to the replacement with a human constant region, the chimeric antibody can retain its specificity in recognizing an antigen while having reduced immunogenicity in humans as compared to the original mouse antibody.

[0039] The term "humanized antibody" is an antibody that retains the antigen-specific reactivity of a non-human antibody (e.g., a mouse monoclonal antibody) while being less immunogenic when administered to humans as a therapeutic agent. Typically, a "humanized antibody" is an antibody in which CDR sequences derived from other mammalian species (e.g., mouse germline) are attached to human framework sequences. Additional framework region modifications can be made within the human framework sequence. In some cases, in order to improve the affinity of the humanized antibody to the antigen, the CDR region or framework region of the humanized antibody can also be backmutated.

[0040] The term "antibody fragment" refers to a molecule, other than an intact antibody, that comprises a portion of an intact antibody and is capable of binding to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; single-chain antibodies (e.g., scFv); single-domain antibodies; and camelid antibodies (heavy chain antibodies).

[0041] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementarity determining regions (CDRs) (see, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007)). A single VH or VL domain is sufficient to confer antigen binding specificity.

[0042] "Complementarity determining region" or "CDR region" or "CDR" is a region of an antibody variable domain that is highly variable in sequence and forms structurally defined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigenic epitopes. The CDRs in the variable domain are typically referred to as CDR1, CDR2, and CDR3 and are numbered sequentially starting from the N-terminus. In a given variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known schemes, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), the international ImMunoGeneTics database (IMGT) (http: / / imgt.cines.fr / ), and affinity propagation clustering based on a large number of crystal structures. The North CDR definition of propagation clustering (North et al., "A New Clustering of Antibody CDR Loop Concepts", Journal of Molecular Biology, 406, 228-256 (2011)).

[0043] For example, different schemes are employed to define different extents of CDR regions using the Kabat and Chothia numbering systems.

[0044] Unless otherwise specified, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined by any of the above schemes.

[0045] CDRs can also be determined based on having the same Kabat numbering position as a reference CDR sequence (e.g., any of the exemplary CDRs of the present invention). Unless otherwise indicated, in the present invention, when referring to residue positions in an antibody variable region (including heavy chain variable region residues and light chain variable region residues), it refers to the position determined according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0046] As used herein, the term "binding" or "specific binding" means that the binding effect is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen binding site to bind to a specific antigen can be determined by conventional methods known in the art, such as radioimmunoassay (RIA), thin-layer interferometry, MSD assay, or surface plasmon resonance (SPR).

[0047] The term "median effective concentration (EC50) 50 )" refers to the concentration of drug, antibody or toxic agent that induces a response that is 50% between baseline and maximum after a specified exposure time.

[0048] The term "half inhibitory concentration (IC50)" refers to the concentration of a test drug or substance that inhibits a measured biological response, biological function or activity by 50% relative to an untreated control.

[0049] The term "treat" refers to slowing, interrupting, arresting, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibodies of the present invention are used to delay disease development or to slow the progression of a disease.

[0050] The term "prevent" includes the inhibition of the development or progression of a disease or condition or symptoms of a particular disease or condition. In some embodiments, subjects with a family history of cancer are candidates for a preventative regimen. Generally, in the context of cancer, the term "prevent" refers to the administration of a drug before the development of signs or symptoms of cancer, particularly in a subject at risk for cancer.

[0051] The term "effective amount" refers to the amount or dosage of an antibody, conjugate, or composition of the invention that produces the desired effect in a patient in need of treatment or prevention after administration to the patient in single or multiple doses. The effective amount can be readily determined by the attending physician, who is skilled in the art, by considering a variety of factors such as the species of mammal; weight, age, and general health; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosing regimen; and the use of any concomitant therapy.

[0052] The term "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. The therapeutically effective amount of an antibody or antibody fragment or conjugate or composition thereof can vary depending on a variety of factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit the desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or conjugate or composition are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70%, and still more preferably at least about 80% or 90% relative to an untreated subject. The ability of a compound to inhibit a measurable parameter (e.g., cancer) can be evaluated in an animal model system that is predictive of efficacy in human tumors.

[0053] The term "prophylactically effective amount" refers to an amount effective to achieve the desired preventive result at the required dosage and for the required period of time. Typically, a prophylactic effective amount will be less than a therapeutically effective amount because a prophylactic dose is used in a subject prior to or at an earlier stage of disease.

[0054] The term "pharmaceutical composition" refers to a composition that is in form permitting the biological activity of the active ingredient contained therein to be effective, and that contains no additional ingredients that are unacceptably toxic to a subject to which the composition would be administered.

[0055] II. Antibodies of the Invention

[0056] Certain specific embodiments of the anti-PVRIG antibodies of the present invention are provided below.

[0057] In one embodiment, the present invention provides an anti-PVRIG antibody and antigen-binding fragment thereof that specifically binds to PVRIG, comprising:

[0058] 1) the three heavy chain CDRs (HCDR1, HCDR2, HCDR3) contained in the heavy chain variable region as shown in SEQ ID NO: 7 and the three light chain CDRs (LCDR1, LCDR2, LCDR3) contained in the light chain variable region as shown in SEQ ID NO: 8;

[0059] 2) the three heavy chain CDRs (HCDR1, HCDR2, HCDR3) contained in the heavy chain variable region as shown in SEQ ID NO: 19 and the three light chain CDRs (LCDR1, LCDR2, LCDR3) contained in the light chain variable region as shown in SEQ ID NO: 20.

[0060] In one embodiment, the present invention provides an anti-PVRIG antibody and antigen-binding fragment thereof that specifically binds to PVRIG, comprising:

[0061] 1) HCDR1, HCDR2, HCDR3 comprising the sequences shown in SEQ ID NOs: 1, 2 and 3, or sequences containing one or more and no more than 3 amino acid substitutions (e.g., conservative substitutions), deletions or insertions relative to the sequences, or consisting of the sequences; and LCDR1, LCDR2, LCDR3 comprising the sequences shown in SEQ ID NOs: 4, 5 and 6, or sequences containing one or more and no more than 3 amino acid substitutions (e.g., conservative substitutions), deletions or insertions relative to the sequences, or consisting of the sequences;

[0062] 2) HCDR1, HCDR2, HCDR3 comprising the sequences shown in SEQ ID NOs: 13, 14 and 15, or sequences containing one or more and no more than 3 amino acid substitutions (e.g., conservative substitutions), deletions or insertions relative to the sequences, or consisting of the sequences; and LCDR1, LCDR2, LCDR3 comprising the sequences shown in SEQ ID NOs: 16, 17 and 18, or sequences containing one or more and no more than 3 amino acid substitutions (e.g., conservative substitutions), deletions or insertions relative to the sequences, or consisting of the sequences.

[0063] In one embodiment, the present invention provides an anti-PVRIG antibody and antigen-binding fragment thereof that specifically binds to PVRIG, comprising a heavy chain variable region, wherein:

[0064] 1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 7, or consists of SEQ ID NO: 7;

[0065] 2) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 9, or consists of SEQ ID NO: 9;

[0066] 3) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 19, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 19, or consists of SEQ ID NO: 19; or

[0067] 4) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 21, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 21, or consists of SEQ ID NO: 21.

[0068] In one embodiment, the present invention provides an anti-PVRIG antibody and antigen-binding fragment thereof that specifically binds to PVRIG, comprising a light chain variable region, wherein:

[0069] 1) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 8, or consists of SEQ ID NO: 8;

[0070] 2) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10, or consists of SEQ ID NO: 10;

[0071] 3) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 20, or consists of SEQ ID NO: 20; or

[0072] 4) the light chain variable region comprises the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 22, or consists of SEQ ID NO: 22.

[0073] In another embodiment, the present invention provides an anti-PVRIG antibody and an antigen-binding fragment thereof that specifically binds to PVRIG, comprising a heavy chain variable region and a light chain variable region, wherein:

[0074] 1) the heavy chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 7, and the light chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 8;

[0075] 2) the heavy chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 9, and the light chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 10;

[0076] 3) the heavy chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 19, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 19, and the light chain variable region comprises, or consists of, the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 20; or

[0077] 4) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:21, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:21, or consists of SEQ ID NO:21, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:22, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:22, or consists of SEQ ID NO:22.

[0078] In some embodiments, the above-mentioned antibodies or antigen-binding fragments thereof further comprise heavy and / or light chain constant region sequences derived from human antibody germline consensus sequences. The light chain constant region is preferably a human kappa or lambda chain constant region. The heavy chain constant region can be a gamma, mu, alpha, delta, or epsilon chain. In some embodiments, the heavy chain constant region is preferably derived from a human IgG1, IgG2, IgG3, or IgG4 constant region sequence.

[0079] It will be appreciated that sequence variants of these constant region domains may also be used, for example comprising one or more amino acid modifications, wherein amino acid positions are identified according to the EU index system of Kabat et al. (1991).

[0080] In one embodiment, the antibody comprises the following heavy and light chains:

[0081] in:

[0082] 1) the heavy chain comprises, or consists of, the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 11, and the light chain comprises, or consists of, the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12; or

[0083] 2) the heavy chain comprises the amino acid sequence of SEQ ID NO:23, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:23, or consists of SEQ ID NO:23, and the light chain comprises the amino acid sequence of SEQ ID NO:24, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:24, or consists of SEQ ID NO:24.

[0084] In certain embodiments of the antibody of any of the foregoing, the antibody is a monoclonal chimeric antibody. In another embodiment, the antibody is a monoclonal humanized antibody.

[0085] In certain embodiments of the antibody of any of the foregoing, the antibody is a full-length antibody.

[0086] In one embodiment, the anti-PVRIG antibody of the present invention is a complete antibody, such as an IgG1, IgG2, IgG3, or IgG4 antibody. In another embodiment, the anti-PVRIG antibody of the present invention encompasses only its antigen-binding portion, such as a Fab, Fab'-SH, Fv, scFv, or (Fab')2 fragment.

[0087] III. Compositions of the Invention

[0088] In some embodiments, the present invention provides a composition comprising any one or more anti-PVRIG antibodies or antigen-binding fragments thereof described herein, preferably a pharmaceutical composition. In one embodiment, the composition further comprises a pharmaceutical excipient, such as a pharmaceutical carrier, a pharmaceutical excipient, including a buffer, as known in the art. In one embodiment, the composition (e.g., a pharmaceutical composition) comprises an anti-PVRIG antibody or antigen-binding fragment thereof of the present invention, and a combination of one or more other therapeutic agents. In some embodiments, other therapeutic agents are selected from antibodies against immune checkpoints (e.g., PD1 / PDL1, LAG3, TIGIG, etc.), antibodies against tumor-associated antigens (e.g., Claudin-18.2, Her2, etc.), and drugs against neovascularization (e.g., VEGF A Ang-2, etc.).

[0089] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.

[0090] For the use of pharmaceutical excipients and their applications, see also "Handbook of Pharmaceutical Excipients", 8th edition, RC Rowe, PJ Eskey and S C Owen, Pharmaceutical Press, London, Chicago.

[0091] The compositions of the present invention can be in a variety of forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusible solutions), powders or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic use.

[0092] The administration route of the composition of the present invention is according to known methods, for example, orally, by intravenous injection, intraperitoneally, intracerebral (intraparenchymal), intracerebroventricular, intramuscularly, intraocularly, intraarterially, intraportally or intralesionally; by sustained release system or by implant device. In certain embodiments, the composition can be administered by bolus injection or by continuous infusion or by implant device.

[0093] The subject can be a mammal, e.g., a primate, preferably a higher primate, e.g., a human (e.g., an individual suffering from a disease described herein or at risk of suffering from a disease described herein). In one embodiment, the subject suffers from a disease described herein (e.g., cancer) or is at risk of suffering from a disease described herein. In certain embodiments, the subject receives or has received other treatments, e.g., chemotherapy and / or radiotherapy. In some embodiments, the subject has previously received or is currently receiving immunotherapy.

[0094] Medicaments comprising the antibodies described herein can be prepared by mixing an anti-PVRIG antibody or antigen-binding fragment thereof of the invention having the desired purity with one or more optional pharmaceutical excipients, preferably in the form of a lyophilized formulation or an aqueous solution.

[0095] The pharmaceutical composition or preparation of the present invention may also include more than one active ingredient, which is required for the specific indication being treated, preferably having those active ingredients of complementary activities that do not adversely affect each other. For example, it is desirable to also provide other therapeutic agents, including chemotherapeutics, angiogenesis inhibitors, cytokines, cytotoxic agents, other antibodies, small molecule drugs or immunomodulators (such as immune checkpoint inhibitors or agonists). The active ingredient is suitably combined in an amount effective for the purpose.

[0096] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, eg, films, or microcapsules.

[0097] The present invention also provides a drug combination comprising the anti-PVRIG antibody or antibody fragment or pharmaceutical composition of the present invention and another drug for treating cancer. In one embodiment, the other drug for treating cancer can be, for example, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, an anti-LAG-3 antibody, an anti-TIM-3 antibody, an anti-BTLA antibody, or a combination of other anti-tumor antibodies. The components of the drug combination can be administered alone or in combination therapy, i.e., in combination with other agents.

[0098] IV. Preparation of Antibodies of the Invention

[0099] In one embodiment, the present invention provides a method for producing an anti-PVRIG antibody or an antigen-binding fragment thereof, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the anti-PVRIG antibody or antigen-binding fragment thereof or an expression vector comprising the nucleic acid under conditions suitable for expression of the nucleic acid encoding the anti-PVRIG antibody or antigen-binding fragment thereof, and optionally isolating the anti-PVRIG antibody or antigen-binding fragment thereof. In a certain embodiment, the method further comprises recovering the anti-PVRIG antibody or antigen-binding fragment thereof from the host cell (or host cell culture medium).

[0100] To recombinantly produce an anti-PVRIG antibody or antigen-binding fragment thereof of the present invention, nucleic acid encoding the anti-PVRIG antibody or antigen-binding fragment thereof of the present invention is first isolated and inserted into a vector for further cloning and / or expression in a host cell. Such nucleic acid is readily isolated and sequenced using conventional procedures, for example, by using oligonucleotide probes that are capable of specifically binding to nucleic acid encoding an anti-PVRIG antibody or antigen-binding fragment thereof of the present invention.

[0101] The anti-PVRIG antibodies or antigen-binding fragments thereof of the present invention, prepared as described herein, can be purified by known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, and hydrophilicity, and will be apparent to those skilled in the art. The purity of the anti-PVRIG antibodies or antigen-binding fragments thereof of the present invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.

[0102] V. Therapeutic Methods and Uses of the Invention

[0103] The present invention provides a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof of the present invention, or a therapeutically effective amount of a pharmaceutical composition of the present invention.

[0104] In one embodiment, the cancer is melanoma, renal cancer, prostate cancer, rectal cancer, colon cancer, breast cancer, stomach cancer, metastatic brain cancer, metastatic liver cancer, lung cancer, non-small cell lung cancer (including squamous cell non-small cell lung cancer), bone cancer, pancreatic cancer, skin cancer, head and neck cancer, uterine cancer, ovarian cancer, lymphoma, blastoma, leukemia.

[0105] In one embodiment, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof of the invention, or a therapeutically effective amount of a pharmaceutical composition of the invention, in combination with a second therapeutic agent.

[0106] In one embodiment, the second therapeutic agent is selected from antibodies against immune checkpoints (such as PD1 / PDL1, LAG3, TIGIG, etc.), antibodies against tumor-associated antigens (such as Claudin-18.2, Her2, etc.), and drugs against neovascularization (such as VEGF A Ang-2, etc.).

[0107] In one embodiment, the present invention provides a method for treating a disease and / or condition requiring blocking of abnormal PVRIG expression, comprising administering to a subject in need thereof an anti-PVRIG antibody as described herein.

[0108] In some embodiments, the present invention provides a method for enhancing NK cell activity, or enhancing the ability of NK cells to kill tumor cells, or enhancing and / or maintaining an anti-tumor immune response in a subject with cancer, the method comprising administering an anti-PVRIG antibody described herein to a subject in need thereof.

[0109] The present invention also provides a combination therapy, that is, the anti-PVRIG antibodies, pharmaceutical compositions, and drug combinations disclosed herein are administered in combination with other treatment modalities. For example, they are administered in combination with other agents (e.g., anti-CTLA-4 antibodies, anti-PD-L1 antibodies, anti-LAG-3 antibodies, anti-TIM-3 antibodies, anti-BTLA antibodies, or other anti-tumor antibodies, or a combination thereof). In one embodiment, the combination therapy further comprises administering the anti-PVRIG antibodies, pharmaceutical compositions, and drug combinations of the present application in combination with radiotherapy, chemotherapy, and / or surgery. In the combination therapy, the anti-PVRIG antibodies, pharmaceutical compositions, and drug combinations of the present application may also be administered separately or sequentially with or without additional therapeutic agents.

[0110] In another aspect, the present invention provides use of an anti-PVRIG antibody or an antigen-binding fragment thereof, or a pharmaceutical composition in the preparation of a medicament for treating cancer.

[0111] In one embodiment, the cancer includes but is not limited to carcinoma, lymphoma, blastoma, sarcoma and leukemia, and more specific examples include: squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer and various types of head and neck cancer.

[0112] In one embodiment, the present invention provides the use of an anti-PVRIG antibody or an antigen-binding fragment thereof, or a pharmaceutical composition for preparing a medicament for enhancing NK cell activity, or enhancing the ability of NK cells to kill tumor cells, or enhancing and / or maintaining an anti-tumor immune response in a subject suffering from cancer. Example

[0113] The present invention is further illustrated by the following examples; however, it should be understood that the examples are described in an illustrative rather than a limiting sense and that various modifications may be made by those skilled in the art.

[0114] Unless expressly stated to the contrary, the present invention will be practiced using conventional methods of chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant DNA technology, genetics, immunology, and cell biology within the skill of the art. The experimental materials used, unless otherwise specified, are commercially available. Where specific techniques or conditions are not specified in the examples, the experiments were performed in accordance with the techniques or conditions described in the literature in the art or in accordance with the corresponding product specifications. Where the manufacturer of the reagents or instruments used is not specified, all are conventional products that can be purchased through regular channels.

[0115] Example 1. Hybridomas producing anti-PVRIG antibodies

[0116] immunity

[0117] According to conventional methods, the extracellular fragment of human PVRIG protein (Acro, Cat#PVG-H52H4) was emulsified with Freund's complete adjuvant (sigma, Cat#F5881) and then immunized into Balb / c mice (purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.). Two weeks later, it was emulsified with Freund's incomplete adjuvant (sigma, Cat#F5506) and immunized three times, with subcutaneous injection once every two weeks (50 μg protein per mouse). Serum was harvested regularly and the serum titer was tested according to conventional methods.

[0118] Cell fusion and high-throughput screening

[0119] When the serum titer meets the requirements, the following operations are performed according to conventional methods: the spleen of the mouse is removed to prepare B lymphocyte suspension, and SP 2 / 0 myeloma cells (ATCC, CRL-1581 TM ) for electrofusion. The fused cells were diluted to 1-2×10 4 Cells were plated at a concentration of 100 μL / mL in a 96-well plate, and 100 μL of cell suspension was added to each well. On day 7 after fusion, the culture medium was replaced with selection medium (1640 medium containing 10% FBS and 1× HT). Supernatants were collected for analysis after culturing for 10 days (or longer depending on cell growth status). Hybridomas specifically expressing anti-PVRIG antibodies were selected by flow cytometry (FACS).

[0120] The hybridoma supernatant was tested for binding to an in-house constructed human PVRIG-expressing cell line (GS-CHO-human PVRIG, see below). GS-CHO-human PVRIG cells were counted and diluted to 1 × 10 6Cells were plated at 100 μL / well of a U-bottom 96-well plate. The plates were centrifuged at 500 g for 5 minutes and the cell culture medium removed. The supernatant from the hybridoma 96-well plate was added to the U-bottom plate and the cells resuspended, with 100 μL added to each well. The cells were incubated on ice for 30 minutes. The supernatant was removed by centrifugation at 500 g for 5 minutes and the cells were washed once with PBS. The cells were centrifuged at 500 g for 5 minutes and the PBS removed. 100 μL of FITC-conjugated secondary antibody (1:500 dilution in PBS) against mouse Fab (Jackson Immunoresearch, Cat#115-545-006) was added to each well. For the positive control antibody, 100 μL of PE-conjugated secondary antibody against human Fc (Biolegend, Cat#409304) was added to each well. The cells were incubated on ice for 30 minutes in the dark. The supernatant was removed by centrifugation at 500 g for 5 minutes and the cells were washed once with PBS. The cells were resuspended in 50 μL of 1× PBS and analyzed by FACS.

[0121] Then, according to conventional methods, the supernatant of the positive clones detected was subjected to a blocking experiment (blocking the binding of PVRIG and its ligand CD112) to screen clones with strong blocking function, subcloned them by limiting dilution method, and single clone cells were picked.

[0122] Positive hybridoma cell subcloning

[0123] The steps for subcloning by limiting dilution are as follows: prepare a 96-well plate and add 200 μL of culture medium to each well. This culture medium is based on the selective culture medium, but HAT is replaced with HT (Gibco, Cat#11067-030). The rest of the formula is the same. Prepare a cell suspension of the positive cells with strong blocking function screened above, take 100 μL and add it to each well of the first row and mix well. Then take 100 μL of the cell suspension from the first row and add it to the second row. After thorough mixing, take 100 μL and add it to the next row. Repeat the above steps, let the 96-well plate stand for 30 minutes, and observe and count under a microscope. Take the volume corresponding to 100 cells and add 20 mL of culture medium, mix well and plate, 200 μL per well. Observe under a microscope one week later to determine and mark the monoclonal wells.

[0124] When the cell confluence in each well reached 50% or higher, the cells were screened using the high-throughput screening method described above. Positive wells were selected, expanded, and then cryopreserved (ultimately, 14 clones were selected). The supernatants from these 14 clones were also subjected to affinity testing using Compugen's COM701 antibody as a positive control. The data are shown in Table 1. The supernatants from these 14 clones were then tested for blocking activity using the same method described above. The results are shown in Table 2.

[0125] Table 1. Affinity determination of the supernatants of 14 positive clones

[0126] Table 2. Cell-level binding and blocking activity of supernatants from 14 positive clones

[0127] Example 2. Construction, expression and purification of antibodies

[0128] The antibody light and heavy chain gene sequences were retrieved from the 14 hybridoma candidate clones obtained in Example 1, and human-mouse chimeric antibodies were constructed from them.

[0129] Take about 5×10 cells of each freshly cultured cell line 6 RNA was extracted from each strain (Macherey-Nagel, Cat# 740984.250). cDNA was obtained by reverse transcription using the PrimeScript II 1st Strand cDNA Synthesis Kit (Takara). Upstream primers were designed based on base sequences in the 5' FR1 region, and downstream primers were designed based on bases in the antibody constant region or FR4 region to amplify the antibody light chain and heavy chain variable region gene fragments. These fragments were ligated into a T-vector (Mighty TA-cloning Kit, Takara), and single clones were selected for sequencing. The sequencing results were analyzed and compared using MEGA7 software.

[0130] After comparison, the antibody light and heavy chain variable region sequences were correct and matched clones, and their light and heavy chain variable region gene fragments were respectively passed through the homologous recombinase ( The IgG1 antibody was ligated into the pcDNA3.1 vector, which also contained the coding sequence of the constant region of the IgG1 subtype, thereby obtaining the corresponding expression plasmids encoding the antibody light chain and heavy chain, respectively.

[0131] The light chain plasmid and heavy chain plasmid of the same antibody were then mixed at a molar ratio of 1:1 and transfected into 293F cells via polyethyleneimine (PEI) (Polysciences, Cat#23966). After 5-7 days of culture, when the cell viability was lower than 60%, the cell culture supernatant was collected and the obtained chimeric monoclonal antibody was purified using a Protein A affinity column.

[0132] Example 3: Determination of the binding kinetics between the chimeric antibody of the present invention and the antigen using biofilm thin layer interferometry (BLI)

[0133] The equilibrium dissociation constant (KD) of the antibody of the present invention binding to human PVRIG was determined using thin-layer biofilm interferometry (ForteBio). ForteBio affinity determination was performed according to existing methods (Estep, P et al., High thro μghput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013. 5(2): p. 270-8). Briefly, an AHQ (Pall, 1506091) sensor was equilibrated offline in assay buffer for 30 minutes, followed by online detection for 60 seconds to establish a baseline. The purified antibody obtained as described above was then loaded online onto the AHQ sensor (ForteBio) for ForteBio affinity measurement. The sensor with the loaded antibody was then exposed to the antigen PVRIG, after which the sensor was transferred to assay buffer for dissociation rate measurement. KD values ​​were analyzed using ForteBio analysis software.

[0134] The test results of representative antibody affinity are shown in Table 3:

[0135] Table 3. Affinity determination of 14 chimeric antibodies

[0136] Example 4 Cell Binding Activity of Chimeric Anti-PVRIG Antibodies

[0137] Flow cytometry was used to detect the binding of the chimeric antibody obtained in Example 3 to the GS-CHO stable cell line overexpressing human PVRIG on its surface.

[0138] The cDNA encoding human PVRIG was cloned into the pCHO1.0 vector (Invitrogen) and then transfected into GS-CHO cells (Invitrogen) to generate GS-CHO cells overexpressing human PVRIG (i.e., GS-CHO-human PVRIG cells). The chimeric antibody was then tested for binding to PVRIG on the cell surface using a serial dilution assay.

[0139] Briefly, GS-CHO-human PVRIG cells were counted and diluted to 2 × 10 6100 μL / well of the diluted 100 μL / well was added to a U-bottom 96-well plate. The cells were centrifuged at 500 g for 5 minutes, and the cell culture medium was removed. Samples (the chimeric antibody, the positive control antibody COM701, and an unrelated IgG negative control antibody) were serially diluted threefold in FACS buffer, starting at a concentration of 300 nM. A total of 12 concentration gradients were established. Each diluted antibody sample was then added to the U-bottom plate and the cells were resuspended. 100 μL / well was added and the cells were incubated at 4°C for 30 minutes. The cells were centrifuged at 500 g for 5 minutes, the supernatant was removed, and the cells were washed twice with FACS buffer. The cells were centrifuged at 500 g for 5 minutes, the FACS buffer was removed, and 100 μL of a PE-conjugated anti-human Fc secondary antibody (Biolegend, Cat#409304) (1:200 dilution in FACS buffer) was added to each well. The cells were incubated at 4°C in the dark for 30 minutes. The cells were centrifuged at 500 g for 5 minutes, the supernatant was removed, and the cells were washed three times with FACS buffer. Resuspend the cells in 200 μL FACS buffer and analyze by flow cytometry.

[0140] The results are shown in Figure 1. Compared with the control antibody COM701, the chimeric antibody had a stronger ability to bind to the human PVRIG molecule overexpressed in GS-CHO cells.

[0141] Example 5 Blocking activity of chimeric anti-PVRIG antibodies

[0142] The ELISA method was used to further detect the ability of the chimeric antibody obtained in Example 3 to block the binding of PVRIG to its ligand CD112.

[0143] Specifically, the extracellular domain of the human PVRIG protein (Acro, #PVG-H52H4) was diluted in coating solution to 1 μg / mL. 100 μL was added to each well of a 96-well microtiter plate (Thermo, #442404) and incubated overnight at 4°C. The coating solution was discarded, and the plates were washed three times with 1x PBST. 200 μL of blocking solution was added to each well and blocked for 1 hour at room temperature. The blocking solution was discarded, and the plates were washed three times with 1x PBST. Samples (chimeric antibody, positive control antibody COM701, and irrelevant negative control IgG) were serially diluted: starting at a 12 μg / mL antibody concentration, the samples were then diluted two-fold in diluent to obtain a total of 12 concentrations. 50 μL was then added to each well of the blocked microtiter plate. Add 50 μL of biotinylated human CD112 protein (Acro, #CD2-H82F8), diluted to 2 μg / mL in diluent, to each well, mix well, and incubate at room temperature for 3 hours. Discard the plate and wash five times with 1x PBST. Add 100 μL of diluted HPR Streptavidin (BioLegend, #405210) to each well and incubate at room temperature for 1 hour. Discard the plate and wash five times with 1x PBST. Add 100 μL of TMB colorimetric solution (Solyb, #PR1200) to each well and develop for 5-10 minutes. Stop the reaction by adding 50 μL of stop solution (Solyb, #C1058) to each well. Read OD450nm and OD620nm using a microplate reader.

[0144] The blocking ability of representative chimeric antibodies and positive control antibodies against PVRIG and CD112 is shown in Figure 2. Compared with the control antibody COM701, the chimeric antibody blocking ability is comparable and can effectively block the binding of PVRIG to its ligand CD112.

[0145] Example 6 Chimeric anti-PVRIG antibody promotes NK cell killing experiment

[0146] Natural killer (NK) cells are a type of innate immune response lymphocyte that can kill tumor cells. PVRIG is expressed on the surface of NK cells and inhibits NK cell activity by binding with high affinity to the ligand CD112 on the surface of tumor cells.

[0147] This example uses an NK cell killing experimental system to further detect the ability of the chimeric antibodies selected in Examples 4 and 5 to mediate NK cell killing activity.

[0148] PBMC (AllCell, #FPB004F-C) were resuscitated using EasySep TMNK cells were isolated using Human NK cell Enrichment kit (STEMCELL, #19055). The isolated NK cells were washed twice with CTSTMAIM VTM medium (gibco, #A3021002), counted, and the cell density was adjusted to 5 × 10 6 / mL. Human chronic myeloid leukemia K562 target cells (ATCC, Cat#CCL-243) were centrifuged at 500 g for 5 min, the cell culture medium was removed, and the cells were washed twice with 1× PBS and labeled with CellTrace Violet (Invitrogen, #C34557). The cells were resuspended in CTSTMAIM VTM medium, and the cell count was adjusted to a density of 1×10 6 / mL. Add 50μL of NK cells, 50μL of K562 cells, and 100μL of test sample diluted to a concentration of 20μg / mL (antibodies ch26E6, ch41D9, ch44F11, ch44G1, and the positive control antibody COM701) to each well of a 96-well U-bottom plate. Incubate in a 37°C, 5% CO2 incubator for 5 hours. Centrifuge at 500g for 5 minutes, then wash twice with FACS buffer. Add diluted PI (BioLegend, #421301) dye and incubate at 4°C for 30 minutes. Wash twice with FACS buffer, and analyze CellTrace Violet- and PI-double-positive cells by flow cytometry.

[0149] Figure 3 shows the NK cell killing mediated by chimeric antibodies ch26E6, ch41D9, ch44F11, and ch44G1. The NK cell killing ability mediated by chimeric antibodies ch26E6 and ch41D9 was comparable to that of the control antibody COM701, while the NK cell killing ability mediated by chimeric antibody ch44G1 was superior to that of the control. This indicates that the chimeric antibodies obtained in this application can effectively enhance the tumor killing ability of NK cells.

[0150] Example 7 Humanization of anti-PVRIG antibody

[0151] The chimeric antibody obtained in Example 5 was humanized according to conventional methods to obtain humanized antibodies: hz44G1.3 and hz41D9.6. The CDR sequences, light chain variable region, and heavy chain variable region sequences of these antibodies, as well as the light chain variable region and heavy chain variable region sequences of the corresponding chimeric antibodies ch44G1 and ch41D9, are shown in Tables AB. The HCDR1 of the antibodies was defined using the Kabat & Chothia definition scheme; the HCDR2 and HCDR3 were defined using the Kabat definition scheme; and the LCDRs were defined using the Kabat definition scheme.

[0152] Table A

[0153] Table B

[0154] Example 8 Humanized anti-PVRIG antibody cell binding experiment

[0155] The binding of the humanized antibody obtained in Example 7 to the GS-CHO stable cell line overexpressing human PVRIG on its surface was detected by flow cytometry. The specific experimental method is as described in Example 4.

[0156] In the experiments described in the above assay, the binding of antibodies hz41D9.6 and hz44G1.3 to GS-CHO-human PVRIG cells is shown in Figure 4. Antibodies hz41D9.6 and hz44G1.3 both bound to human PVRIG molecules overexpressed in GS-CHO cells with EC50 values ​​of 1.32 nM and 2.03 nM, respectively, demonstrating stronger binding than the control antibody COM701.

[0157] Example 9 Humanized anti-PVRIG antibody blocking experiment

[0158] ELISA was used to detect the ability of the humanized antibody of the present invention, which was diluted in a gradient manner, to block the binding of PVRIG to its ligand CD112. The specific experimental steps are shown in Example 5.

[0159] In the experiments described in the above assay, the blocking effects of antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3 on PVRIG / CD112 are shown in Figure 5. Among them, antibodies hz41D9.6 and hz44G1.3 can both block the binding of PVRIG to CD112, with IC50 values ​​of 0.08 μg / mL and 0.14 μg / mL, respectively. Compared with the control antibody COM701, these antibodies can more effectively block the binding of PVRIG to its ligand CD112.

[0160] Example 10 Humanized anti-PVRIG antibody promotes NK cell killing experiment

[0161] The NK cell killing assay system was used to detect the NK cell killing function mediated by the humanized antibody obtained in Example 7. The specific experimental steps were as described in Example 6.

[0162] In the experiments described in the above assay, the NK cell killing mediated by antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3 is shown in Figure 6. Compared with the control antibody COM701, antibody hz44F11E11.6 was comparable to the control, and antibody hz44G1.3 mediated NK cell killing activity that was superior to the control COM701. This demonstrates that these humanized antibodies can effectively enhance the tumor-killing ability of NK cells.

[0163] Example 11 Humanized anti-PVRIG antibody promotes NK cell activation experiment

[0164] NK cells were used to further detect the activation ability of the humanized antibody obtained in Example 7.

[0165] PBMC (AllCell, #FPB004F-C) were resuscitated using EasySep TM NK cells were isolated using Human NK cell Enrichment kit (STEMCELL, #19055). The isolated NK cells were washed twice with CTSTMAIM VTM medium (Gibco, #A3021002), counted, and the cell density was adjusted to 2 × 10 6 / mL. Take K562 target cells, centrifuge at 500g for 5 minutes, remove the cell culture medium, wash twice with CTSTMAIM VTM medium, count and adjust the cell density to 1×10 6 / mL. 50 μL of NK cells, 50 μL of K562 cells, and 100 μL of test sample diluted to 20 μg / mL (antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3, positive control antibody COM701, and irrelevant negative control IgG) were added to each well of a 96-well U-bottom plate. The cells were incubated at 37°C in a 5% CO2 incubator for 16 hours. After centrifugation at 500 g for 5 minutes, the cell culture medium was removed and the cells were washed twice with FACS buffer. The prepared antibodies (BV421 anti-CD3 (BioLegend, #300434), PE anti-NKp46 (BioLegend, #331908), and APC anti-CD137 (BioLegend, #309810)) were then added and incubated at 4°C for 30 minutes. The cells were washed twice with FACS buffer and the proportion of CD137+ cells in CD3-NKp46+ cells was detected by flow cytometry.

[0166] In the experiments described in the above assays, the effects of antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3 on NK cell activation are shown in Figure 7. Compared to the control antibody COM701, humanized antibody hz41D9.6 mediated NK cell activation comparable to that of the control, while hz44F11E11.6 and hz44G1.3 exhibited stronger NK cell activation.

[0167] Example 12 Humanized anti-PVRIG antibody promotes NK cell degranulation experiment

[0168] The NK cell degranulation experiment was used to detect the regulatory effect of the humanized antibody obtained in Example 7 on NK cell function.

[0169] PBMC (AllCell, #FPB004F-C) were resuscitated using EasySep TM NK cells were isolated using Human NK cell Enrichment kit (STEMCELL, #19055), washed twice with CTSTMAIM VTM medium (gibco, #A3021002), counted, and adjusted to a cell density of 2 × 10 6 50 μL of NK cells and 150 μL of CTSMAIM VTM medium were added to each well of a 96-well U-bottom plate and cultured overnight in a 37°C, 5% CO2 incubator.

[0170] K562 target cells were centrifuged at 500 g for 5 min, the cell culture medium was removed, and the cells were washed twice with CTSTMAIM VTM medium. The cell density was counted and adjusted to 1 × 10 6Carefully discard 150 μL / well of the supernatant from the overnight NK cell culture. Add 50 μL of K562 cells and 100 μL of the test sample diluted to 20 μg / mL (antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3, as well as the positive control antibody COM701 and an irrelevant negative control IgG). PE anti-CD107a (BioLegend, #328608) and Monensin (BioLegend, #420701) were added to the sample dilution buffer. Incubate in a 37°C, 5% CO2 incubator for 4 hours. Centrifuge at 500 g for 5 minutes, discard the supernatant, wash twice with FACS buffer, then add the prepared antibodies (BV421 anti-CD3 (BioLegend, #300434), AF488 anti-NKp46 (BioLegend, #331938)), and incubate at 4°C for 30 minutes. Wash twice with FACS buffer, and measure the proportion of CD107a+ cells in CD3-NKp46+ cells by flow cytometry.

[0171] In the experiments described in the above assay, the NK cell degranulation mediated by antibodies hz41D9.6, hz44F11E11.6, and hz44G1.3 is shown in Figure 8. Compared with the control antibody COM701, the humanized antibodies hz44F11E11.6 and hz44G1.3 of the present invention have stronger NK cell degranulation ability.

[0172] Example 13 Therapeutic Effects of Humanized Anti-PVRIG Antibodies in a PBMC Xenograft DNG-18.2 Tumor Model

[0173] The anti-tumor effect of the anti-PVRIG antibody of the present invention was determined by inoculating NDG huIL15 mice with DAN-G / Claudin18.2 cells.

[0174] NDG huIL15 mice:

[0175] Female NDG huIL15 mice were purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd. and were SPF-grade. The quality control unit was Suzhou Xishan Biotechnology Co., Ltd., and the quality control certificate number was No. 320726210100350582. The mice were acclimated for 3 days after arrival before the study began.

[0176] cell:

[0177] DAN-G / Claudin18.2 cells were obtained from Innovent. For detailed construction methods, see WO2021254481. Conventional subculture was used for subsequent in vivo experiments. Cells were collected by centrifugation and resuspended in sterile PBS to a cell density of 5 × 10 6 On day 0, 0.2 mL of cell suspension was subcutaneously inoculated into the right abdominal region of NDG huIL15 mice to establish a DAN-G / Claudin18.2-NDG huIL15 tumor-bearing mouse model.

[0178] PBMC reconstitution and drug administration;

[0179] Five days after tumor cell inoculation, each mouse was intravenously injected with 4×10 6 PBMC cells (AllCell, #FPB004F-C) were inoculated and randomly divided into groups (6 mice per group) on the 7th day. The dosage and method of administration are shown in Table 4. h-IgG (purchased from EQUITECH-BIO) was used as a negative control and administered on days 7, 10, 13, 17, 20, and 24 after inoculation. The tumor volume and body weight of the mice were monitored twice a week starting from day 10. Body weight and tumor volume were measured before each administration. The relative tumor inhibition rate (TGI%) was calculated on day 38 after inoculation using the following formula: TGI% = 100% × (tumor volume of control group – tumor volume of treatment group) / (tumor volume of control group – tumor volume of control group before administration). Tumor volume measurement: The maximum long axis (L) and maximum wide axis (W) of the tumor were measured using a vernier caliper. The tumor volume was calculated using the following formula: V = L × W 2 / 2. Body weight was measured using an electronic balance.

[0180] Table 4. Experimental design

[0181] On day 38, the tumor inhibition rate of COM701 antibody was 36%, while the tumor inhibition rates of hz41D9.6 antibody, hz44F11E11.6 antibody, and hz44G1.3 antibody were 73%, 67%, and 56%, respectively (Table 5). Compared with the h-IgG-10 mg / kg group, COM701-10 mg / kg had a certain inhibitory effect on the growth of DAN-G / Claudin18.2 tumors, while hz41D9.6-10 mg / kg, hz44F11E11.6-10 mg / kg, and hz44G1.3-10 mg / kg had a significant inhibitory effect on the growth of DAN-G / Claudin18.2 tumors. Compared to COM701-10 mg / kg, hz41D9.6-10 mg / kg, hz44F11E11.6-10 mg / kg, and hz44G1.3-10 mg / kg demonstrated enhanced inhibitory effects on DAN-G / Claudin18.2 tumor growth. As shown in Figure 9, no significant weight loss was observed in any of the groups of mice during the dosing period, but graft-versus-host disease (GVHD) developed on day 38 after inoculation. Weight loss was most pronounced in the group treated with the control molecule COM701, while hz44G1.3 showed no significant difference compared to the IgG group, indicating a manageable drug safety profile. Consequently, the anti-PVRIG antibodies of the present invention exhibited significant tumor inhibitory effects, surpassing those of COM701.

[0182] Table 5. Tumor inhibition rate on day 38

[0183] Example 14 Dose effect of humanized anti-PVRIG antibody-mediated NK cell killing in vitro

[0184] The humanized antibody of the present invention is applied to an NK cell killing experimental system to study the dosage effect of the antibody in promoting NK cell killing.

[0185] PBMC (AllCell, #FPB005F-C) were resuscitated using EasySep TM NK cells were isolated using Human NK cell Enrichment kit (STEMCELL, #19055). The isolated NK cells were washed twice with CTSTMAIM VTM medium (gibco, #A3021002), counted, and the cell density was adjusted to 3 × 10 6 / mL. Take K562 target cells, centrifuge at 500g for 5 minutes, remove the cell culture medium, wash twice with CTSTMAIM VTM medium, resuspend in CTSTMAIM VTM medium, count and adjust the cell density to 2×10 6 / mL. 50μL NK cells, 25μL K562 cells, and 25μL diluted test sample (antibodies hz41D9.6 and hz44G1.3, positive control antibody COM701, and irrelevant negative control IgG, respectively) were added to each well of a 96-well plate. The antibody dilution method was as follows: the starting antibody concentration was 40μg / mL, and the antibody was diluted 10-fold in the diluent to obtain a total of 10 concentrations. Set up background control: K562 target cells; set up maximum killing control: use CytoTox Target cells were lysed using the lysis buffer provided with the Non-Radioactive Cytotoxicity Kit (PROMEGA, #G1780) according to the manufacturer's instructions and incubated in a 37°C, 5% CO2 incubator for 4 hours.

[0186] Using CytoTox Non-Radioactive Cytotoxicity Kit (Promega) was used to detect the concentration of LDH in the supernatant. 12 mL of Assay Buffer was added to the Substrate Mix under dark conditions and mixed thoroughly. 50 μL of the culture supernatant was placed in an ELISA plate and 50 μL of CytoTox was added to each well. Reagent, react at room temperature for 1 hr, add 50 μL Stop Solution to terminate, detect OD490 with a microplate reader, and analyze the data.

[0187] % lysis = 100 × (ER-SR1) / (MR-SR1)

[0188] ER: LDH release from experimental wells; SR1: LDH release from target cell control wells; MR: maximum LDH release (lysed target cells).

[0189] In the experiments described in the above assays, the dose-response effect of antibodies hz41D9.6 and hz44G1.3 in promoting NK cell killing is shown in Figure 10. Antibodies hz41D9.6 and hz44G1.3 mediated NK cell killing in a dose-response manner. Compared with the control antibody COM701, antibodies hz41D9.6 and hz44G1.3 mediated NK cell killing in a dose-response manner, which was stronger than that of the control antibody COM701.

Claims

1. An anti-PVRIG antibody or an antigen-binding fragment thereof that specifically binds to PVRIG, comprising: 1) three heavy chain CDRs (HCDR1, HCDR2, HCDR3) contained in the heavy chain variable region as shown in SEQ ID NO:7 and three light chain CDRs (LCDR1, LCDR2, LCDR3) contained in the light chain variable region as shown in SEQ ID NO:8; or 2) the three heavy chain CDRs (HCDR1, HCDR2, HCDR3) contained in the heavy chain variable region as shown in SEQ ID NO: 19 and the three light chain CDRs (LCDR1, LCDR2, LCDR3) contained in the light chain variable region as shown in SEQ ID NO:

20.

2. An anti-PVRIG antibody or antigen-binding fragment thereof that specifically binds to PVRIG, comprising: 1) comprising HCDR1, HCDR2, HCDR3 of the sequences shown in SEQ ID NOs: 1, 2 and 3; and LCDR1, LCDR2, LCDR3 of the sequences shown in SEQ ID NOs: 4, 5 and 6; or 2) comprising HCDR1, HCDR2, HCDR3 of the sequences shown in SEQ ID NOs: 13, 14 and 15; and LCDR1, LCDR2, LCDR3 of the sequences shown in SEQ ID NOs: 16, 17 and 18.

3. The anti-PVRIG antibody or antigen-binding fragment thereof according to claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, wherein: 1) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:7, or consists of SEQ ID NO:7, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:8, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:8, or consists of SEQ ID NO:8; 2) the heavy chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:9, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:9, or consists of SEQ ID NO:9, and the light chain variable region comprises the amino acid sequence as set forth in SEQ ID NO:10, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:10, or consists of SEQ ID NO:10; 3) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:19, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:19, or consists of SEQ ID NO:19, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:20, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:20, or consists of SEQ ID NO:20; or 4) the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 21, or a residue identical to SEQ ID NO: 21; The invention further comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:21, or consists of SEQ ID NO:21, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:22, or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:22, or consists of SEQ ID NO:

22.

4. The isolated anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the antigen-binding fragment is selected from Fab, Fab'-SH, Fv (eg, scFv) or (Fab')2 fragment.

5. The isolated anti-PVRIG monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 4, comprising a constant region sequence, wherein at least a portion of the constant region sequence is a human consensus constant region sequence.

6. The isolated anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising a heavy chain and a light chain, wherein: 1) the heavy chain comprises the amino acid sequence of SEQ ID NO:11, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:11, or consists of SEQ ID NO:11, and the light chain comprises the amino acid sequence of SEQ ID NO:12, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:12, or consists of SEQ ID NO:12; or 2) the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:23, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:23, or consists of SEQ ID NO:23, and the light chain comprises the amino acid sequence as shown in SEQ ID NO:24, or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:24, or consists of SEQ ID NO:

24.

7. A pharmaceutical composition comprising: (1) the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, and; (2) Pharmaceutically acceptable carrier.

8. An isolated polynucleotide molecule encoding the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.

9. A vector comprising the nucleic acid molecule according to claim 8, preferably, the vector is an expression vector. 10 . A host cell comprising the vector according to claim 9 or the nucleic acid molecule according to claim 8 .

11. Use of the anti-PVRIG antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, and the pharmaceutical composition according to claim 7 in the preparation of a medicament for treating cancer.

12. A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, or a therapeutically effective amount of the pharmaceutical composition according to claim 7.

13. The use or method of claim 11 or 12, wherein the cancer includes but is not limited to carcinoma, lymphoma, blastoma, sarcoma and leukemia, and more specific examples include: Squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, and various types of head and neck cancer.

14. A pharmaceutical combination comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 or the pharmaceutical composition according to claim 7, and other therapeutic agents for treating cancer.

15. The drug combination of claim 14, wherein the other therapeutic agents for treating cancer are selected from anti-CTLA-4 antibodies, anti-PD-L1 antibodies, anti-LAG-3 antibodies, anti-TIM-3 antibodies, anti-BTLA antibodies, other anti-tumor antibodies or combinations thereof, radiotherapy, chemotherapy, or surgical therapy.

Citation Information

Patent Citations

  • Anti-PVRIG antibody formulations and uses thereof

    CN114615993A

  • Combination therapy of anti-PVRIG antibody formulations and anti-PD-1 antibodies

    CN114980922A

  • Antibody of PVRIG or antigen binding fragment thereof and application thereof

    CN115819582A

  • Anti-pvrig protein antibody or antibody fragment, and use thereof

    WO2022188721A1

  • Anti-tigit and Anti-pvrig in monotherapy and combination treatments

    WO2023275621A1